Literature DB >> 33566720

Meningococcal vaccines in China.

Yinghua Xu1, Yanan Li1, Shanshan Wang1, Maoguang Li1, Miao Xu1, Qiang Ye1.   

Abstract

Meningococcal meningitis caused by Neisseria meningitidis is a reportable infectious disease in China, due to the high incidence of meningitis in the era before the availability of vaccines. The disease incidence was markedly reduced after meningococcal vaccination was introduced in the 1980s. Currently, there are polysaccharide, conjugate, and combined vaccine formulations against meningococcal meningitis in the Chinese market, almost all of which are produced by domestic manufacturers. It is necessary to further enhance national meningococcal surveillance to improve the level of prevention and control of meningococcus. However, the immune efficacy and persistence of immunity of vaccines should be monitored. More importantly, additional investments should be made to develop serogroup B meningococcal vaccines.

Entities:  

Keywords:  China; Neisseria meningitidis; conjugate vaccines; invasive meningococcal disease; polysaccharides vaccines; quality control

Mesh:

Substances:

Year:  2021        PMID: 33566720      PMCID: PMC8189055          DOI: 10.1080/21645515.2020.1857201

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  50 in total

1.  Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002.

Authors:  Richard Brooks; Christopher W Woods; Daniel K Benjamin; Nancy E Rosenstein
Journal:  Clin Infect Dis       Date:  2006-05-24       Impact factor: 9.079

2.  Post-marketing study on the safety of a meningococcal group A, C bivalent polysaccharide conjugate vaccine.

Authors:  Chuanxi Fu; Guihua Huang; Min Cui; Ming Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-06       Impact factor: 3.452

3.  [Analysis of epidemic characteristics for meningococcal meningitis in China during 2015-2017].

Authors:  J H Li; D Wu; Z D Yin; Y X Li
Journal:  Zhonghua Yu Fang Yi Xue Za Zhi       Date:  2019-02-06

4.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

5.  [Immunizing reactivity following vaccination with a purified fraction of Neisseria meningitidis and observations of effectiveness throughout 3 years].

Authors:  R T Wei
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  1982-02

Review 6.  Neisserial Molecular Adaptations to the Nasopharyngeal Niche.

Authors:  Jay R Laver; Sara E Hughes; Robert C Read
Journal:  Adv Microb Physiol       Date:  2015-05-30       Impact factor: 3.517

7.  Quantitation of serogroups in multivalent polysaccharide-based meningococcal vaccines: optimisation of hydrolysis conditions and chromatographic methods.

Authors:  Matthew C Cook; Alex Bliu; Jeremy P Kunkel
Journal:  Vaccine       Date:  2013-06-10       Impact factor: 3.641

Review 8.  Burden of Neisseria meningitidis infections in China: a systematic review and meta-analysis.

Authors:  Yaowen Zhang; Dong Wei; Xinzhen Guo; Mai Han; Lichao Yuan; Moe H Kyaw
Journal:  J Glob Health       Date:  2016-12       Impact factor: 4.413

9.  Description and nomenclature of Neisseria meningitidis capsule locus.

Authors:  Odile B Harrison; Heike Claus; Ying Jiang; Julia S Bennett; Holly B Bratcher; Keith A Jolley; Craig Corton; Rory Care; Jan T Poolman; Wendell D Zollinger; Carl E Frasch; David S Stephens; Ian Feavers; Matthias Frosch; Julian Parkhill; Ulrich Vogel; Michael A Quail; Stephen D Bentley; Martin C J Maiden
Journal:  Emerg Infect Dis       Date:  2013-04       Impact factor: 6.883

10.  Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors:  E C Gotschlich; T Y Liu; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.